Therapeutic cloning: promises and issues
McGill Journal of Medicine · 01.12.2020 · 10 (2)
DOI: 10.26443/mjm.v10i2.450 ↗Kurz gefasst
Fachartikel in der Zeitschrift McGill Journal of Medicine, online erschienen am 01.12.2020. Verfasst von Charlotte Kfoury. Die Arbeit wurde bisher 6-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
Advances in biotechnology necessitate both an understanding of scientific principles and ethical implications to be clinically applicable in medicine. In this regard, therapeutic cloning offers significant potential in regenerative medicine by circumventing immunorejection, and in the cure of genetic disorders when used in conjunction with gene therapy. Therapeutic cloning in the context of cell replacement therapy holds a huge potential for de novo organogenesis and the permanent treatment of Parkinson's disease, Duchenne muscular dystrophy, and diabetes mellitus as shown by in vivo studies. Scientific roadblocks impeding advancement in therapeutic cloning are tumorigenicity, epigenetic reprogramming, mitochondrial heteroplasmy, interspecies pathogen transfer, low oocyte availability. Therapeutic cloning is also often tied to ethical considerations concerning the source, destruction and moral status of IVF embryos based on the argument of potential. Legislative and funding issues are also addressed. Future considerations would include a distinction between therapeutic and reproductive cloning in legislative formulations.
Zitieren
APA
Kfoury, C. (2020). Therapeutic cloning: promises and issues. McGill Journal of Medicine, 10(2). https://doi.org/10.26443/mjm.v10i2.450
Vancouver
Kfoury C. Therapeutic cloning: promises and issues. McGill Journal of Medicine. 2020;10(2). doi:10.26443/mjm.v10i2.450
BibTeX
@article{Kfoury2020,
author = {Kfoury, Charlotte},
title = {Therapeutic cloning: promises and issues},
journal = {McGill Journal of Medicine},
year = {2020},
volume = {10},
number = {2},
doi = {10.26443/mjm.v10i2.450}
}
EUVIMED